Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Portfolio Pulse from
Wall Street analysts predict a significant upside of 136.83% for Day One Biopharmaceuticals (DAWN), driven by strong consensus in raising earnings estimates.
November 06, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have set a mean price target for Day One Biopharmaceuticals (DAWN) that suggests a 136.83% upside. This is supported by a strong consensus in raising earnings estimates, indicating potential growth.
The article highlights a significant potential upside for DAWN based on analysts' price targets and a strong consensus in raising earnings estimates. This suggests positive sentiment and potential growth, likely leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100